Exhibit 10.27

CONFIDENTIAL TREATMENT REQUESTED

Portions of this Exhibit have been redacted pursuant to a request for
confidential treatment under Rule 24b-2 of the General Rules and Regulations
under the Securities Exchange Act of 1934, as amended. Such redacted portions
have been replaced with “***” in this Exhibit. An unredacted version of this
document has been filed separately with the Securities and Exchange Commission
along with the request for confidential treatment

NON-EXCLUSIVE LICENSE AGREEMENT

This Non-Exclusive License Agreement (this “Agreement”) is entered into this
27th day of March, 2012 (the “Effective Date”), by and between Caliper Life
Sciences Corporation, a Delaware corporation having a principal place of
business at 68 Elm Street, Hopkinton, MA 01748 (“Licensor”), and Clinical Micro
Sensors, Inc. d/b/a GenMark Diagnostics, Inc., a Delaware corporation having a
principal place of business at 5964 La Place Court, Carlsbad, CA 92008
(“Licensee”), each also referred to herein individually as a “Party” and
collectively as “Parties.”

WHEREAS, Licensor is engaged in research, development and commercialization
efforts towards the miniaturization, integration and automation of laboratory
equipment, and owns certain patent rights associated therewith;

WHEREAS, Licensee is engaged in the research, development and commercialization
of Microfluidics Technology (as defined below) including instruments, software
and microfluidic chips;

WHEREAS, the Parties wish to fully and finally resolve all patent issues
associated with the aforementioned microfluidics patent rights, upon the terms
and subject to the conditions set forth below, and thereby avoid the substantial
costs, uncertainty and risk involved with prolonged patent-infringement
litigation, trial and appeal;

WHEREAS, Licensee desires to obtain and Licensor desires to grant to Licensee a
non-exclusive license to certain patent rights of Licensor for the research,
development and commercialization of certain devices and instruments for use in
the Field.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set
forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

1. DEFINITIONS.

 

  1.1 Affiliate(s). “Affiliate(s)” shall mean any person or entity which
controls, is controlled by or is under common control with a Party. For the
purposes of this Section 1.1, “control” means (a) it owns or controls at least
fifty percent (50%) of the equity securities of entity Party and is entitled to
vote such securities in the election of directors (or, in the case of an entity
that is not a corporation, for the election of the corresponding managing
authority), or (b) it has the power to directly or indirectly direct or cause
the direction of the board of directors or equivalent governing body of entity
Party.

 

  1.2 Calendar Quarter. “Calendar Quarter” shall mean the respective periods of
three (3) consecutive calendar months ending on March 31, June 30, September 30
or December 31.

 

  1.3 Calendar Year. “Calendar Year” shall mean the periods of twelve
(12) consecutive calendar months ending on December 31.

--------------------------------------------------------------------------------

  1.4 Change of Control. “Change of Control” shall mean, with respect to the
Licensee, any merger or other transaction or series of transactions (a) which
results in the holders of voting securities of Licensee outstanding immediately
prior thereto failing to continue to represent (either by remaining outstanding
or by being converted into voting securities of the surviving entity) more than
fifty percent (50%) of the combined voting power of the voting securities of
Licensee outstanding immediately after such merger or transaction or series of
transactions, or (b) in which a Third Party acquires all or substantially all of
Licensee’s business, capital stock outstanding, or assets to which this
Agreement applies, whether by merger, acquisition, sale, or otherwise.

 

  1.5 Combination Product. “Combination Product” shall mean a product or
combination of products, sold, transferred or otherwise disposed of at a single
price, that contains or consists of a Licensed Product and at least one other
product that is not a Licensed Product.

 

  1.6 Confidential Information. “Confidential Information” shall mean any
information provided to Licensor pursuant to Article 3 of this Agreement, and
the terms of this Agreement.

 

  1.7 Control or Controlled. “Control” or “Controlled” shall mean, with respect
to any intellectual property right (including any Patent Rights), the possession
(whether by ownership or license, or otherwise) by a Party of the ability to
grant to the other Party a license or other right as provided herein under such
intellectual property without violating the terms of any written agreement
existing before the Effective Date with a Third Party.

 

  1.8 Diagnostic Applications. “Diagnostic Applications” shall mean applications
and any and all uses that if performed in the United States would require
clearance or approval by the U.S. Food and Drug Administration (FDA) through the
premarket notification (510(k)) or premarket approval (PMA) process and any and
all in vitro diagnostic applications and uses (including those exempt from FDA
premarket clearance or approval).

 

  1.9 Field. “Field” shall mean all human Diagnostic Applications, excluding:
(a) newborn screening and maternal/fetal prenatal testing, except for the
screening and/or testing of cystic fibrosis, and (b) nucleic acid or protein
separation, fractionation and life science applications.

 

  1.10 GAAP. “GAAP” shall mean United States generally accepted accounting
principles, consistently applied.

 

  1.11 Improvement Patents. “Improvement Patents” shall mean any and all Patent
Rights Controlled by Licensor or its Affiliates relating to and within the scope
of Microfluidics Technology and that has been first conceived and reduced to
practice by Licensor or its Affiliates after the Effective Date and during the
Term of this Agreement.

 

2

--------------------------------------------------------------------------------

  1.12 Licensed Product. “Licensed Product” shall mean a product (a) Proprietary
to Licensee and (b) the manufacture, use, sale, offer for sale or importation of
which would, but for the licenses granted herein, infringe a Valid Claim within
the Licensed Patents.

 

  1.13 Licensed Patents. “Licensed Patents” shall mean Patent Rights Controlled
by Licensor as of the Effective Date of this Agreement that claim or relate to
Microfluidics Technology, including those listed in Exhibit A attached hereto;
provided, however, that “Licensed Patents” shall not include intellectual
property (a) licensed by Licensor from Monogram Biosciences, Inc., or
(b) directed to imaging chemistry, imaging automation and/or imaging
instrumentation technologies. For clarity, “Licensed Patents” includes any
patent that claims or relates to Microfluidics Technology issued following the
Effective Date from a patent application filed on or prior to the Effective Date
or that claims priority to a patent or patent application filed on or before the
Effective Date.

 

  1.14 Microfluidics Technology. “Microfluidics Technology” shall mean
compositions of matter, methods and other technology applicable to moving fluids
through, and/or modifying chemical and/or biochemical reactions within, channels
or chambers, including methods for the manufacture or use of any Microfluidic
Device and any devices or software used in connection with any Microfluidic
Device. “Microfluidics Technology” shall also include compositions of matter,
methods and other technology relating to (a) the structure, design, and
manufacture of such fluidics devices, (b) the interfacing of such fluidics
devices to external Instruments, (c) the control of fluid movement within, into,
and out of such fluidics devices, (d) performing experiments and/or separations
within such fluidics devices, (e) the detection of experimental results from or
in association with such fluidic devices, and (f) software relating to each of
the foregoing.

 

  1.15 Microfluidic Device. “Microfluidic Device” shall mean a consumable device
comprising a microfluidic or mesofluidic channel(s).

 

  1.16 Net Sales. “Net Sales” shall mean:

the amount of revenue actually received by Licensee or its Affiliate(s), during
any specified period in accordance with GAAP for the sale, transfer, or other
disposition of a Licensed Product, less the following deductions to the extent
applicable to such amounts: (i) all trade, cash and quantity credits, discounts,
rebates or refunds; (ii) credits or allowances for returns, billing errors,
damaged, outdated or recalled Licensed Products, in each case during such
period; and (iii) packaging costs, handling fees, insurance and prepaid freight,
sales taxes, duties and other governmental charges (including value-

 

3

--------------------------------------------------------------------------------

added tax), but excluding what is commonly known as income taxes; provided that
if a Licensed Product is so sold or otherwise transferred for a single price in
the form of a Combination Product, Net Sales shall be further calculated
pursuant to Section 1.16(b) below;

Notwithstanding the foregoing, in the event that, in any given Calendar Quarter,
a Licensed Product is sold as part of a Combination Product, the amount of
revenue received for such Licensed Product shall be calculated by multiplying
the revenue received for such Combination Product by the fraction A/(A+B) where
“A” is the average revenue received for such Licensed Product(s) sold separately
during such Calendar Quarter, and “B” is the average revenue received for the
other items included in such Combination Product sold separately during such
Calendar Quarter.

In the event that such separate sales of components in a Combination Product
were not made or performed during the applicable Calendar Quarter, then the
amount of revenue received for a Licensed Product that is sold as part of a
Combination Product shall be calculated by multiplying the amount of revenue
received for the Combination Product by *** percent (***%). The parties agree
that any allocation of revenue from the sale or other disposition of Combination
Products pursuant to this Section 1.16(b) shall be done in good faith, and shall
take into consideration revenue recognition guidance under GAAP which is
applicable to multiple-deliverable revenue arrangements.

Net Sales shall not include sales between or among Licensee and its Affiliate;
provided that if Licensee sells a Licensed Product to an Affiliate for resale,
Net Sales shall include sales by such Affiliate in accordance with GAAP in
connection with the resale of such Licensed Product to a Third Party.

Notwithstanding anything else in this in this section, the supply or other
disposition of Licensed Products without charge as (i) samples, or (ii) for use
in any tests or studies reasonably necessary to comply with any applicable law,
regulation or request by a regulatory or governmental authority or as is
otherwise reasonable and customary in the industry, in each case shall not be
included within the computation of Net Sales.

 

  1.17 Patent Rights. “Patent Rights” shall mean any and all patents, patent
applications, including any and all divisionals, continuations,
continuations-in-part, reissues, reexaminations, restorations (including
supplemental protection certificates) and extensions, pipeline protection,
invention certificates, and substitutions of any of the above.

 

  1.18 Proprietary to Licensee. “Proprietary to Licensee” shall mean, with
respect to any product, either: (a) Licensee owns, or exclusively or
co-exclusively licenses, a Patent Right that covers the making, using, selling,
offering for

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

4

--------------------------------------------------------------------------------

  sale, or import of such product, or (b) the product embodies or incorporates
any other property or intellectual property right owned by or exclusively or
co-exclusively licensed to Licensee. In the event of a Change of Control of
Licensee, following such Change of Control the term “Proprietary to Licensee”
shall be based on (a) the Patent Rights and/or (b) other such property or
intellectual property right owned or licensed or otherwise protected by Licensee
as a trade secret that are in existence immediately prior to the consummation of
such Change of Control transaction, and improvements thereto.

 

  1.19 Royalty Term. “Royalty Term” shall mean the period of time beginning on
the Effective Date and, on a Licensed Product-by-Licensed Product, and
country-by-country basis, extending until the date on which the last Valid Claim
included within the Licensed Patents covering such Licensed Product in such
country ceases to be a Valid Claim.

 

  1.20 Territory. “Territory” shall mean the entire world.

 

  1.21 Third Part(y/ies). “Third Part(y/ies)” shall mean any person(s) or
entit(y/ies) other than Licensee, Licensor or their respective Affiliates.

 

  1.22 Valid Claim. “Valid Claim” shall mean an issued and unexpired claim of
any United States or foreign Patent Right, which claims has not been donated to
the public, cancelled, withdrawn, abandonded, disclaimed, or revoked, or held
invalid or unenforceable by a court or government agency of competent
jurisdiction in an unappealed or unappealable decision.

 

2. GRANT OF LICENSE

 

  2.1 License to Licensed Patents. Subject to the terms and conditions of this
Agreement, Licensor hereby grants to Licensee and its Affiliates a
non-exclusive, royalty-bearing license under the Licensed Patents to make, have
made, use, import, export, offer for sale, sell and otherwise commercialize
Licensed Products in the Territory in the Field. Under the license granted
pursuant to this Section 2.1, Licensee shall be permitted to authorize the use
of the Licensed Products by its customers within the Field. The license rights
granted to Licensee pursuant to this Section 2.1 shall not include any right to
grant any sublicenses under the Licensed Patents, except (i) as may be required
to enable Licensee to distribute Licensed Products via an authorized distributor
or other reseller, or (ii) as may be necessary for Licensee to have a Third
Party design, develop or manufacture Licensed Products in collaboration with or
for Licensee. Licensed Products shall be sold only by Licensee, it Affiliates or
authorized distributors or resellers.

 

  2.2

Option to Improvement Patents. Subject to the terms and conditions of this
Agreement, Licensor grants to Licensee an option to obtain a non-exclusive,
royalty-bearing license under the Improvement Patents to make,

 

5

--------------------------------------------------------------------------------

  have made, use, import, export, offer for sale, sell and otherwise
commercialize Licensed Products in the Territory in the Field. Licensee may
exercise this option at any time during the first two (2) years of this
Agreement by providing written notice to Licensor. If Licensee exercises its
option to Improvement Patents, the Parties shall negotiate in good faith to
determine the specific terms and conditions on which the license shall be
granted by Licensor to Licensee, in accordance with generally accepted industry
standards.

 

  2.3 No Implied Licenses. Nothing herein shall be construed as granting
Licensee, by implication, estoppel or otherwise, any license or other right to
any intellectual property of Licensor other than the Licensed Patents or to
grant to Licensee any right or license other than those expressly granted
herein.

 

3. CONSIDERATION.

 

  3.1 Initial License Fee. Licensee shall pay to Licensor a license fee in the
amount of *** United States Dollars ($***) in consideration for the license
granted to the Licensed Patents. This license fee shall be payable on or before
March 31, 2012, and shall be fully earned by Licensor on the Effective Date. In
the event that Licensee does not pay the license fee to Licensor as provided in
this Section 3.1, Licensee’s license rights under the Licensed Patents pursuant
to this Agreement shall be terminated after written notice and Licensee’s
failure to cure within thirty (30) days of such notice.

 

  3.2 Royalty Payments. During the Term of this Agreement, as additional
consideration for the license and rights granted to Licensee pursuant to
Section 2.1 above, for each Calendar Quarter (or portion thereof) during the
Royalty Term, Licensee shall pay running royalties on Net Sales of Licensed
Products to Licensor as follows:

 

  (i) ***% of those Net Sales of Licensed Products during a particular Calendar
Year between US$*** and US$***;

 

  (ii) ***% of those Net Sales of Licensed Products during a particular Calendar
Year between US$*** and US$***; and

 

  (iii) ***% of those Net Sales of Licensed Products during a particular
Calendar Year greater than US$***;

For clarity, no royalty shall be due on Net Sales of Licensed Products in any
Calendar Year less than $***.

In order to calculate the running royalty payment to be paid for each Calendar
Quarter, aggregate Net Sales of Licensed Products occurring

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

6

--------------------------------------------------------------------------------

between the start of the applicable Calendar Year in which the Calendar Quarter
falls to the end of that Calendar Quarter, and the associated royalty rate tiers
achieved and surpassed, shall be used.

 

  3.3 Royalty Stacking. If Licensee or an Affiliate has obtained or obtains a
license(s) from Third Party(ies) for Microfluidics Technology that Licensees
reasonably believes is necessary or useful to make, have made, use, sell, offer
for sale or import any Licensed Product, Licensee may deduct or credit ***
percent (***%) of any royalties payable to such Third Party(ies) from or against
running royalties due to Licensor pursuant to this Agreement, provided that in
no event shall the running royalties paid to Licensor be reduced by more than
*** percent (***%) of the royalties otherwise owed to Licensor absent such
deduction or credit. In the event that Licensee claims the benefit of the
provisions of this Section 3.3, Licensee shall provide Licensor with reasonable
evidence, for example, evidence from a license agreement or royalty report,
supporting the amounts deducted or credited against royalties due to Licensor.
Licensee’s obligation to provide any such evidence shall be subject to any
obligation of Licensee to a Third Party restricting or preventing the disclosure
of such information. All information of Licensee which is provided to Licensor
under this Section 3.3 shall be deemed to be Licensee’s Confidential Information
subject to the provisions of Article 5 hereof.

 

  3.4 Single Royalty. Notwithstanding anything herein to the contrary, with
respect to any Licensed Product for which a royalty payment is due only a single
royalty payment shall be due and payable, regardless if such Licensed Product is
covered by more than one Valid Claim.

 

  3.5 Milestone Payments. As additional consideration for the rights granted to
Licensee pursuant to Section 2.1 above, Licensee shall also pay to Licensor the
following one-time milestone payments, each distinct and not subsumed by
another:

 

  (a) $*** no later than thirty (30) days after the end of the first Calendar
Year in which cumulative Net Sales of Licensed Products following the Effective
Date first exceed $***;.

 

  (b) $*** no later than thirty (30) days after the end of the first Calendar
Year in which cumulative Net Sales of Licensed Products following the Effective
Date first exceed $***;

 

  (c) $*** no later than thirty (30) days after the end of the first Calendar
Year in which cumulative Net Sales of Licensed Products following the Effective
Date first exceed $***; and

 

  (d) $*** no later than thirty (30) days after a Change of Control of Licensee.

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

7

--------------------------------------------------------------------------------

  3.6 Royalty Statements and Payments. Licensee, within forty five (45) days
after the end of each Calendar Quarter, shall deliver to Licensor a report
setting forth for such Calendar Quarter the following information, on a
Licensed-Product-by-Licensed-Product basis: (a) the Net Sales of each Licensed
Product, (b) the cumulative Net Sales of Licensed Products occurring since the
start of the applicable Calendar Year and since the Effective Date, and (c) the
royalties due hereunder for such Net Sales of each Licensed Product. The total
running royalty due for the sale or other disposition of Licensed Products
during such Calendar Quarter shall be remitted at the time such report is made.
Any royalties not paid when due in accordance with this Section 3.6 accrue
interest from the date due at the “bank prime loan” rate (as defined in the U.S.
Federal Reserve Bulletin H.15 or any successor thereto) on the last business day
of the applicable Calendar Quarter prior to the date on which such payment is
due, plus *** percent (***%) per annum, calculated on the basis of a 360-day
year.

 

  (a) Taxes and Withholding. All payments under this Agreement will be made
without any deduction or withholding for or on account of any tax unless such
deduction or withholding is required by applicable laws or regulations. If
Licensee is so required to deduct or withhold, Licensee will (i) promptly notify
Licensor of such requirement, and (ii) upon request, promptly forward to
Licensor an official receipt (or certified copy) or other available
documentation evidencing such payment to such authorities.

 

  (b) Currency. All amounts payable and calculations hereunder shall be in
United States dollars. As applicable, Net Sales and any deductions therefrom
shall be translated into United States dollars at the daily 12 noon buying rate
certified by the New York Federal Reserve Bank on the last date of the
applicable Calendar Quarter.

 

  (c) Blocked Currency. If at any time legal restrictions prevent the prompt
remittance of part or all of payments owed by Licensee with respect to any
country in the Territory where Licensed Products are sold, royalty payments on
Net Sales of Licensed Products due hereunder shall continue to accrue, and shall
continue to be reported, until such time payment shall be made through any
lawful means or methods that may be available as Licensee shall reasonably
determine.

 

  3.7 Maintenance of Records; Audits.

 

  (a) Record Keeping. Licensee shall keep, and shall cause its Affiliates to
keep, accurate books and accounts of record in connection with the sale of
Licensed Products, in sufficient detail to permit accurate determination and
verification of the running royalties to be paid hereunder. Licensee and its
Affiliates shall maintain such records for a period of at least three (3) years
after the end of the Calendar Year to which they pertain.

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

8

--------------------------------------------------------------------------------

  (b) Audits. Upon not less than thirty (30) days prior written notice from
Licensor, Licensee shall permit an independent certified public accounting firm
selected by Licensor and reasonably acceptable to Licensee, to examine, at
Licensor’s sole expense, the relevant books and records of Licensee and its
Affiliates necessary to verify the accuracy of the reports submitted by Licensee
in accordance with Section 3.6 and the payment of royalties hereunder. An
examination by Licensor under this Section 3.6 shall occur not more than once in
any Calendar Year and shall be limited to the pertinent books and records for
any Calendar Year ending not more than three (3) years before the date of the
request, and shall not be permitted more than once with respect to records
covering any specific period of time. The accounting firm shall be provided
access to such books and records at Licensee’s facility(ies) where such books
and records are normally kept and such examination shall be conducted during
Licensee’s normal business hours upon reasonable advance notice by Licensor
solely to verify the accuracy of the reports submitted by Licensee in accordance
with Section 3.6 and the payment of royalties hereunder; provided that such
independent certified public accounting firm has entered into a written
agreement with Licensee limiting the use of such records to verification of the
accuracy of royalties due under this Agreement and prohibiting the disclosure of
any information contained in such records to a Third Party for any purpose and
to Licensor for a purpose other than as set forth in this Section. Upon
completion of the audit, the accounting firm shall provide both Licensee and
Licensor with a written report including a numerical summary of payments due and
paid, and a description of the basis for any discrepancy therebetween.

 

  (c) Underpayments. If the accounting firm retained pursuant to Section 3.7(b)
concludes that additional running royalties were due to Licensor, Licensee shall
pay to Licensor the additional running royalties within thirty (30) days of the
date Licensee receives such accountant’s written report so concluding. Any
overpayment made by Licensee shall be fully creditable against amounts payable
in subsequent payment periods. If the accountant’s written report concludes that
Licensee made an overpayment, but the Royalty Term of the Agreement has expired,
Licensor shall refund the uncontested portion of the overpayment to Licensee
within thirty (30) days of the date Licensor receives such accountant’s written
report. If Licensee has underpaid royalties due to Licensor hereunder by more
than seven and one-half percent (7.5%), then, provided the audited period
includes at least four (4) consecutive Calendar Quarters, Licensee shall pay the
reasonable expenses of the accounting firm retained pursuant to this
Section 3.7.

 

9

--------------------------------------------------------------------------------

  (d) Confidentiality. All financial information of Licensee which is subject to
review under this Section 3.6 shall be deemed to be Licensee’s Confidential
Information subject to the provisions of Article 5 hereof.

 

  3.8 Form of Payments. Unless otherwise mutually agreed in writing, any and all
payments to Licensor required under this Agreement shall be made by wire
transfer to:

***

 

4. INTELLECTUAL PROPERTY.

 

  4.1 Filing, Prosecution and Maintenance of Licensed Patents. Licensor, at its
own expense, shall have the sole right to prepare, file, prosecute and maintain,
throughout the world, all of the Licensed Patents. Upon Licensee’s written
request, Licensor shall provide Licensee with information regarding the current
status of any Patent Rights included in the Licensed Patents, and any related
documentation. Nothing in this Agreement shall be deemed to limit Licensor’s
ability to abandon any of the Licensed Patents.

 

5. CONFIDENTIALITY.

 

  5.1 Confidentiality. Except to the extent expressly authorized by this
Agreement or otherwise agreed in writing, the Parties agree that, for the term
of this Agreement and for five (5) years thereafter, each Party (the “Receiving
Party”) receiving any Confidential Information of the other Party (the
“Disclosing Party”) hereunder shall keep such Confidential Information
confidential and shall not publish or otherwise disclose or use such
Confidential Information for any purpose other than as provided for in this
Agreement, except for Confidential Information that the Receiving Party can
establish:

 

  (a) was already known by the Receiving Party (other than under an obligation
of confidentiality) at the time of disclosure by the Disclosing Party;

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

10

--------------------------------------------------------------------------------

  (b) was available to the public or otherwise part of the public domain at the
time of its disclosure to the Receiving Party;

 

  (c) became available to the public or otherwise part of the public domain
after its disclosure to the Receiving Party other than through any act or
omission of a Party in breach of this Agreement;

 

  (d) was disclosed to the Receiving Party by a Third Party who had no
obligation to the Disclosing Party not to disclose such information to others;
or

 

  (e) was independently discovered or developed by or on behalf of the Receiving
Party without the use of the Confidential Information.

Notwithstanding the foregoing, each Party may disclose the other Party’s
Confidential Information and the terms of this Agreement to its advisors,
consultants, investors and potential acquirers who have a need to know such
Confidential Information and are bound by obligations of confidentiality and
non-use substantially similar to those set forth herein.

 

  5.2 Authorized Disclosure. Notwithstanding the foregoing Section 5.1, each
Party may disclose Confidential Information belonging to the other Party to the
extent such disclosure is reasonably necessary to:

 

  (a) exercise rights hereunder provided such disclosure is covered by terms of
confidentiality similar to those set forth herein, or

 

  (b) comply with applicable governmental laws and regulations.

In the event the Receiving Party shall deem it necessary to disclose
Confidential Information pursuant to this Section 5.2(b), the Receiving Party
shall, to the extent possible, give reasonable advance notice of such disclosure
to the Disclosing Party and provide reasonable assistance to allow the
Disclosing Party to seek confidential treatment of such information.

 

  5.3 SEC Filings. Notwithstanding Section 5.2, Either Party may disclose the
terms of this Agreement to the extent required, in the reasonable opinion of
such Party’s legal counsel, to comply with applicable laws, including, without
limitation, the rules and regulations promulgated by the United States
Securities and Exchange Commission. Before disclosing this Agreement or any of
the terms hereof pursuant to this Section 5.3, the Parties will consult with one
another on the terms of this Agreement to be redacted in making any such
disclosure.

 

  5.4 Public Announcements. Except as may be expressly permitted under
Section 5.3, neither party will make any public announcement regarding this
Agreement without the prior written approval of the other Party.

 

11

--------------------------------------------------------------------------------

6. REPRESENTATIONS AND WARRANTIES.

 

  6.1 Representations and Warranties of Each Party. Each of Licensor and
Licensee hereby represents and warrants to the other Party as follows:

 

  (a) it is a corporation or entity duly organized and validly existing under
the laws of the state or other jurisdiction of its incorporation or formation;

 

  (b) the execution, delivery and performance of this Agreement by such Party
has been duly authorized by all requisite corporate action;

 

  (c) it has the power and authority to execute and deliver this Agreement and
to perform its obligations hereunder on behalf of itself and its Affiliates as
of the Effective Date of this Agreement;

 

  (d) the execution, delivery and performance by such Party of this Agreement
and its compliance with the terms and provisions hereof does not and will not
conflict with or result in a breach of any of the terms and provisions of or
constitute a default under (i) any agreement or instrument binding or affecting
it or its property; (ii) the provisions of its charter or operative documents or
bylaws; or (iii) any order, writ, injunction or decree of any court or
governmental authority entered against it or by which any of its property is
bound; and

 

  (e) the person executing this Agreement has all power and authority necessary
to do so.

 

  6.2 Disclaimer. EXCEPT AS PROVIDED IN THIS ARTICLE 6, NEITHER PARTY MAKES ANY
WARRANTIES OR CONDITIONS (EXPRESS, IMPLIED, STATUTORY OR OTHERWISE) WITH RESPECT
TO THE SUBJECT MATTER HEREOF, AND LICENSOR SPECIFICALLY DISCLAIMS ANY AND ALL
IMPLIED WARRANTIES OR CONDITIONS OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE, AND ALL WARRANTIES AND CONDITIONS OF THE VALIDITY OF THE LICENSED
PATENTS OR NONINFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.

 

  6.3 Representation by Legal Counsel. Each Party hereto represents that it has
been represented by legal counsel in connection with this Agreement and
acknowledges that it has participated in the drafting hereof. In interpreting
and applying the terms and provisions of this Agreement, the Parties agree that
no presumption shall exist or be implied against the party which drafted such
terms and provisions.

 

12

--------------------------------------------------------------------------------

  6.4 Indemnity. Licensee shall indemnify, defend and hold harmless Licensor and
its respective officers, employees, and agents, and their respective successors
and assigns (the “Indemnitees”) against any third party liability, damage, loss
or expense (including reasonable attorney’s fees and expenses of litigation)
incurred by or imposed upon the Indemnitees or any one of them in connection
with any claim, suit, action, demand or judgment arising directly out of
Licensee, its Affiliates or authorized distributors or resellsers’ manufacture,
use, sale, offer for sale or import of Licensed Products. Licensee’s
indemnification shall not apply to any liability, damage, loss or expense to the
extent that it is attributable to the acts or omissions of the Indemnitees. The
foregoing obligation of indemnity is subject to the condition that the
Indemnitee shall promptly notify Licensee on being notified or otherwise made
aware of a liability, claim, suit, action, demand or judgment and that Licensee
defend and control any proceedings using counsel of its choice (with Licensor
being permitted to participate at its own expense); provided, that, an
Indemnitee may not settle any liability, claim, suit, action, demand or
judgment, or otherwise consent to any judgment, without the written consent of
Licensee.

 

  6.5 No Other Microfluidics Patent Rights. Licensor represents and warrants
that, as of the Effective Date, there are no Patent Rights Controlled by it or
its Affiliates, other than the Licensed Patents, that claim or relate to
compositions of matter, methods and other technology applicable to moving fluids
through, and/or modifying chemical and/or biochemical reactions within, meso or
micro scale channels or chambers, including methods for the manufacture or use
of any consumable devices comprising such channels or chambers and any devices
or software used in connection therewith (including any compositions of matter,
methods and other technology relating to (a) the structure, design, and
manufacture of such fluidics devices, (b) the interfacing of such fluidics
devices to external Instruments, (c) the control of fluid movement within, into,
and out of such fluidics devices, (d) performing experiments and/or separations
within such fluidics devices, (e) the detection of experimental results from or
in association with such fluidic devices, and (f) software relating to each of
the foregoing).

 

7. TERM AND TERMINATION.

 

  7.1 Term. The term of this Agreement will commence on the Effective Date and
extend in perpetuity, unless this Agreement is terminated earlier in accordance
with this Article 7, on a Licensed-Product-by-Licensed-Product, and
country-by-country basis until such time as the Royalty Term with respect to the
sale of such Licensed Product in such country expires.

 

  7.2

Termination for Breach. This Agreement may be terminated effective immediately
by written notice by either Party at any time during the term of this Agreement
for material breach by the other Party, which breach remains

 

13

--------------------------------------------------------------------------------

  uncured for sixty (60) days, measured from the date written notice of such
breach is given to the breaching Party; provided, however, that if such breach
is not susceptible of cure within such sixty (60) day period and the breaching
Party uses diligent good faith efforts to cure such breach, such period will be
extended as reasonably necessary to cure such breach. However, if Licensee is
alleged to be in breach of Article 3 of this Agreement, and Licensee disputes in
good faith such breach by written notice to Licensor within such sixty (60) day
period (which notice shall set forth in reasonable detail the basis for
Licensee’s belief that it is not in default under this Agreement), Licensor
shall not have the right to terminate this Agreement until (a) it has been
determined through the dispute resolution process provided in Section 9.2 of
this Agreement, that Licensee has materially breached Article 3 of this
Agreement, and (b) Licensee fails, within thirty (30) days after such
determination, to pay, if any, all accrued and unpaid royalties due under this
Agreement, together with interest in accordance with Article 3.

 

  7.3 Bankruptcy.

 

  (a) Termination Upon a Bankruptcy Event. To the extent permitted by applicable
law, each Party shall have the right to terminate this Agreement upon written
notice to the other party in the event of a Bankruptcy Event with respect to the
other Party. “Bankruptcy Event” means the occurrence of any of the following:
(a) the institution of any bankruptcy, receivership, insolvency, reorganization
or other similar proceedings by or against a party under any bankruptcy,
insolvency, or other similar law now or hereinafter in effect, including any
section or chapter of the U.S. Bankruptcy Code, as amended or under any similar
laws or statutes of the United States or any state thereof, where in the case of
involuntary proceedings such proceedings have not been dismissed or discharged
within one hundred (120) days after they are instituted, (b) the making of an
assignment for the benefit of creditors as to all or substantially all of a
party’s assets, or (c) the appointment of a receiver, custodian, trustee,
liquidator, assignee or other similar official for all or substantially all of a
party’s assets.

 

  (b) Rights under Bankruptcy Code. All rights and licenses granted under or
pursuant to this Agreement by Licensor are, and shall otherwise be deemed to be,
for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights
to “intellectual property” as defined under Section 101 of the U.S. Bankruptcy
Code. The parties agree that Licensee, as licensee of intellectual property
under this Agreement, shall retain and may fully exercise all of its rights and
elections under the U.S. Bankruptcy Code.

 

14

--------------------------------------------------------------------------------

  7.4 Termination by Licensee. Licensee shall have the right, exercisable upon
thirty (30) days prior written notice to Licensor, to terminate this Agreement.

 

  7.5 Termination by Licensor. Licensor shall have the right to terminate this
Agreement if Licensee or an Affiliate of Licensee, after the Effective Date,
institutes a suit, reexamination, nullity action, opposition to grant, or other
legal action in that country, seeking to invalidate the claims of a Licensed
Patent, or if Licensee or an Affiliate of Licensee actively participates (other
than by legal compulsion) in any of the foregoing (a “Patent Challenge”), except
if such Patent Challenge is in whole or part made in defense of a suit or other
action against or threatened against Licensee or any of its Affiliates. Such
termination shall be effective thirty (30) days after written notice by Licensor
to Licensee, unless, within such thirty (30) days, Licensee (or its applicable
Affiliate) withdraws such Patent Challenge; provided, however, that if any delay
in such withdrawal is caused by an act or omission by Licensor or any of its
Affiliates, such 30-day period shall be extended for a period of time equal to
the amount of delay caused by Licensor or its Affiliate.

 

  7.6 Effects of Termination. Upon termination of this Agreement for any reason
other than a material, uncured breach by Licensor, all licenses granted by
Licensor to Licensee hereunder will automatically terminate and be of no further
force and effect; provided, however, that Licensee shall have the rights for a
reasonable period of time, not to exceed six (6) months, to dispose of existing
inventory of Licensed Products, and further provided that all provisions
relating to earned royalty obligations set forth herein shall survive
termination as to any Licensed Products sold after the effective date of
termination.

 

  7.7 Survival of Certain Obligations. Expiration or termination of the
Agreement shall not relieve the Parties of any obligation accruing before such
expiration or termination, and the applicable provisions of Article 1, 5 and 8,
and Sections 3.7, this Section 7.7, Section 9.7 and Section 9.10 shall survive
the expiration or termination of the Agreement. Any expiration or early
termination of this Agreement shall be without prejudice to the rights of either
Party against the other accrued or accruing under this Agreement before
termination, including, without limitation, the obligations to pay royalties for
Licensed Products sold before such termination.

 

8. RELEASE.

 

  8.1

Release by Licensor. Licensor, on behalf of itself, and its predecessors,
successors and assigns, and any parents, subsidiaries and Affiliates, does
hereby now and forever release and discharge Licensee, and its predecessors,
successors and assigns, and any parents, subsidiaries and other Affiliates,

 

15

--------------------------------------------------------------------------------

  and each of their respective current and former officers, directors,
employees, agents, attorneys, and representatives (individually and
collectively, the “Released Parties”) from any and all known or unknown claims,
damages, actions, causes of actions, defenses, demands, costs or charges, in law
or equity, based upon any Released Parties’ manufacture, use, marketing, sale,
offering for sale, import or distribution of Licensed Products on or prior to
the Effective Date.

 

  8.2 Waiver Of California Civil Code Section 1542 With Respect To The Released
Claims. Each Party acknowledges familiarity with the provisions of Section 1542
of the California Civil Code and expressly waives and releases any rights or
benefits arising thereunder. Section 1542 of the California Civil Code states:

“A general release does not extend to claims which the creditor does not know or
suspect to exist in his favor at the time of executing the release, which if
known by him must have materially affected his settlement with the debtor.”

 

9. MISCELLANEOUS.

 

  9.1 Assignment. Neither this Agreement nor any interest hereunder shall be
assignable by Licensee, without the prior written consent of Licensor, which
consent shall not be unreasonably withheld or delayed. Notwithstanding the
foregoing, Licensor may freely assign this Agreement to an Affiliate or in
connection with the sale of all or substantially all of its assets, to which
this Agreement pertains, and Licensee may freely assign this Agreement in
connection with a Change of Control provided that the provisions of
Section 3.4(d) have been complied with. This Agreement shall be binding upon the
successors and permitted assigns of the Parties and the name of a Party
appearing herein shall be deemed to include the names of such Party’s successors
and permitted assigns to the extent necessary to carry out the intent of this
Agreement. Any assignment not in accordance with this Section 9.1 shall be void.

 

  9.2 Dispute Resolution. Except as set forth below, Any disputes under this
Agreement shall be determined in a dispute resolution process as outlined in
this Section 9.2.

 

  (a)

Senior Management Consultation. Each Party agrees that, as a first step in any
dispute resolution, it shall give the other Party written notice of its
grievance and request and participate in a meeting with a senior executive of
the other Party to discuss the matter in order to consider informal and amicable
means of resolution, and refrain from

 

16

--------------------------------------------------------------------------------

  formal dispute resolution for a period of thirty (30) days after such notice
to allow for such a meeting (such time being extendable for good cause by mutual
agreement).

 

  (b) Binding Arbitration. If the Parties are unable to resolve their dispute
informally through senior management consultation, as contemplated by this
Section 9.2., then either Party may demand binding arbitration before JAMS,
using the then current JAMS comprehensive arbitration rules and procedures, in
which arbitration the following procedures shall control:

 

  (i) The dispute shall be submitted to a single JAMS arbitrator for resolution.

 

  (ii) If possible, the arbitrator shall be selected jointly by the Parties. If
the Parties are unable to agree, an arbitrator shall be selected in accordance
with the rules and procedures of JAMS.

 

  (iii) Each Party shall be entitled to submit to the other party one set of
document requests and one set of simple interrogatories numbering no more than
twenty (20), and to take no more than five (5) depositions lasting no more than
twenty (20) hours in the aggregate.

 

  (iv) After exchange and submission of briefs by each Party, each main brief
not to exceed twenty five (25) pages and reply brief ten (10) pages, each Party
shall have a total of two hours in which to argue its case to the arbitrator,
unless the arbitrator believes that a decision on the briefs is preferable which
shall be entirely his or her decision. All evidence shall be submitted by
declaration under oath. There will be no live testimony at the hearing.

 

  (v) A decision shall be rendered by the arbitrator in writing within thirty
(30) days of the submission of the dispute by the parties to the arbitrator for
resolution, which decision shall be final and binding on the Parties.

 

  (vi) The arbitrator shall have no power to award any relief other than
injunctive relief and monetary relief for damages actually incurred, and
appropriate declaratory relief with respect to disputed issues under, in
connection with, or arising out of this Agreement.

 

  (vii) The Parties shall bear their own attorneys fees and costs of the
arbitration, except that the arbitrator may, in his or her discretion, award
attorneys’ fees and costs to the prevailing Party, or a portion thereof, upon a
finding that the non-prevailing party acted in bad faith.

 

17

--------------------------------------------------------------------------------

  (viii) If the winning Party does not receive the full amount and benefit of
the arbitration result from the losing party within thirty (30) days of the
decision, the winning Party may resort to the courts of the Commonwealth of
Massachusetts to obtain a Court order against the losing Party, and the losing
Party shall bear all the costs of the winning Party in such procedure.

Notwithstanding foregoing, any dispute not resolved internally by the Parties
pursuant to Section 9.2(a) that involves the validity, infringement or
enforceability of a Licensed Patent (a) that is issued in the United States
shall be subject to actions before the United States Patent and Trademark Office
and/or submitted exclusively to the federal court located in the jurisdiction of
the district where any of the defendants reside; and (b) that is issued in any
other country (or region) shall be brought before an appropriate regulatory or
administrative body or court in that country (or region), and the Parties hereby
consent to the jurisdiction and venue of such courts and bodies.

 

  9.3 Force Majeure. Neither Party shall be liable to the other for delay or
failure in the performance of the obligations on its part contained in this
Agreement if and to the extent that such failure or delay is due to
circumstances beyond its control which it could not have avoided by the exercise
of reasonable diligence. It shall notify the other Party as soon as reasonably
possible should such circumstances arise, giving an indication of the likely
extent and duration thereof, and shall use all reasonable efforts to resume
performance of its obligations as soon as practicable; provided, however, that
neither Party shall be required by this Section 9.3 to settle any labor dispute
or disturbance.

 

  9.4 Correspondence and Notices. Any notices required hereunder shall be in
writing and shall be deemed given if delivered personally or by facsimile
transmission (receipt verified), mailed by registered or certified mail (return
receipt requested), postage prepaid, or sent by nationally recognized express
courier service, to the Parties at the following addresses (or at such other
address for a Party as shall be specified by like notice; provided, however,
that notices of a change of address shall be effective only upon receipt
thereof).

All correspondence to Licensee shall be addressed as follows:

GenMark Diagnostics, Inc.,

5964 La Place Court

Carlsbad, CA 92008

 

18

--------------------------------------------------------------------------------

Attn: Corporate Secretary

Fax: (760) 448-4301

All correspondence to Licensor shall be addressed as follows:

Caliper Life Sciences Corporation

68 Elm Street

Hopkinton, MA 01748

Attn: Asst. General Counsel

Fax: (774) 278-2726

with a copy to:

PerkinElmer Health Sciences, Inc.

940 Winter Street

Waltham, MA 02451

Attn: General Counsel

Fax: (781) 663-5970

 

  9.5 Amendment. No amendment, modification or supplement of any provision of
this Agreement shall be valid or effective unless made in writing and signed by
a duly authorized officer of each Party.

 

  9.6 Waiver. No provision of this Agreement shall be waived by any act,
omission or knowledge of a Party or its agents or employees except by an
instrument in writing expressly waiving such provision and signed by a duly
authorized officer of the waiving Party.

 

  9.7 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY
OR ANY THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, EXEMPLARY OR INCIDENTAL
DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES OR PROFITS RELATING TO THE
SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS
BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN
AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR
LIKELIHOOD OF SAME.

 

  9.8 Severability. If any clause or portion thereof in this Agreement is for
any reason held to be invalid, illegal or unenforceable, the same shall not
affect any other portion of this Agreement, as it is the intent of the Parties
that this Agreement shall be construed in such fashion as to maintain its
existence, validity and enforceability to the greatest extent possible. In any
such event, this Agreement shall be construed as if such clause of portion
thereof had never been contained in this Agreement, and there shall be deemed
substituted therefor such provision as will most nearly carry out the intent of
the Parties as expressed in this Agreement to the fullest extent permitted by
applicable law.

 

19

--------------------------------------------------------------------------------

  9.9 Interpretation. The descriptive headings of this Agreement are for
convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement. In this Agreement, the
singular shall include the plural and vice versa and the word “including” shall
be deemed to be followed by the phrase “without limitation.”

 

  9.10 Governing Law. This Agreement shall be governed by and interpreted in
accordance with the substantive laws of the Delaware, without regard to conflict
of law principles thereof.

 

  9.11 Entire Agreement of the Parties. This Agreement constitutes and contains
the complete, final and exclusive understanding and agreement of the Parties and
cancels and supersedes any and all prior negotiations, correspondence,
understandings and agreements, whether oral or written, among the Parties
respecting the subject matter hereof and thereof.

 

  9.12 Independent Contractors. Both Parties are independent contractors under
this Agreement. Nothing herein contained shall be deemed to create an
employment, agency, joint venture or partnership or fiduciary relationship
between the parties hereto or any of their agents or employees, or any other
legal arrangement that would impose liability upon one Party for the act or
failure to act of the other Party. Neither Party shall have any express or
implied power to enter into any contracts or commitments or to incur any
liabilities in the name of, or on behalf of, the other Party, or to bind the
other Party in any respect whatsoever.

 

  9.13 Counterparts. This Agreement may be executed in any number of
counterparts, each of which need not contain the signature of more than one
party but all such counterparts taken together shall constitute one and the same
agreement. Execution and delivery may be evidenced by a facsimile or electronic
transmission of a signed copy of this Agreement.

[Signature Page Follows]

 

20

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, duly authorized representatives of the parties have duly
executed this Agreement to be effective as of the Effective Date.

 

CLINCAL MICRO SENSORS, INC.     CALIPER LIFE SCIENCES CORPORATION By  

/s/ Hany Massarany

    By  

/s/ Alan Fletcher

Name:   Hany Massarany      Name:   Alan Fletcher Title:   President and CEO  
   Title:   VP & GM, New Markets

 

21

--------------------------------------------------------------------------------

EXHIBIT A

LICENSED PATENTS

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   DE    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

2

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   DE    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EDV    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   KR    DIV    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

3

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    DIV    Pending    CLS    ***    ***    ***      

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

4

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPC    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

5

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   GB    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

6

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPC    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

7

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

8

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

9

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   CH    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

10

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

11

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    PCT    Pending    CLS    ***    ***    ***      

***

   EP    EPP    Pending    CLS    ***    ***    ***      

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

12

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

13

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

14

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

15

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

16

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Pending    CLS    ***    ***    ***      

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

17

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    DIV    Pending    CLS    ***    ***    ***      

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Pending    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

18

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Pending    CLS    ***    ***    ***      

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPC    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

19

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

20

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    PCT    Pending    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Allowed    CLS    ***    ***    ***      

***

   EP    DIV    Pending    CLS    ***    ***    ***      

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

21

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   JP    DIV    Pending    CLS    ***    ***    ***      

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

22

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    DIV    Pending    CLS    ***    ***    ***      

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

23

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

24

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Allowed    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

25

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Pending    CLS    ***    ***    ***      

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    DIV    Allowed    CLS    ***    ***    ***      

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

26

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    DIV    Pending    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    RCE    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

27

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

28

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CIP    Pending    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

29

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   MX    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

30

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   JP    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EDV    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

31

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS &

AGIL

   ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

32

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

33

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    ORD    Pending    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

34

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Pending    CLS    ***    ***    ***      

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   IN    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

35

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Pending    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

36

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   FR    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    PCT    Allowed    CLS    ***    ***    ***      

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

37

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   DE    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

38

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    PCT    Pending    CLS    ***    ***    ***      

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    CIP    Pending    CLS &
CANON    ***    ***    ***      

***

   EP    ORD    Pending    CLS &
CANON    ***    ***    ***      

***

   IN    ORD    Pending    CLS &
CANON    ***    ***    ***      

***

   JP    CIP    Pending    CLS &
CANON    ***    ***    ***      

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

39

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Pending    CLS &
CANON    ***    ***    ***      

***

   WO    ORD    Pending    CLS &
CANON    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Pending    CLS    ***    ***    ***      

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

40

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    CON    Pending    CLS    ***    ***    ***      

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

41

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   FR    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CTC    ***    ***    ***    ***    ***

***

   CH    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

42

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Pending    CLS    ***    ***    ***      

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

43

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Allowed    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    DIV    Allowed    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

44

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    PCT    Pending    CLS    ***    ***    ***      

***

   EP    PCT    Pending    CLS    ***    ***    ***      

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

45

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   DE    EPP    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   ES    PCT    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   FR    ORD    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   GB    ORD    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   IT    EPP    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   US    PCT    Pending    CLS &
WAKO    ***    ***    ***      

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    DIV    Allowed    CLS    ***    ***    ***      

***

   JP    DIV    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

46

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   JP    EPP    Pending    CLS    ***    ***    ***      

***

   US    EPP    Pending    CLS    ***    ***    ***      

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Pending    CLS    ***    ***    ***      

***

   CH    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

47

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   KR    PCT    Granted    CLS &
WAKO    ***    ***    ***    ***    ***

***

   IN    PCT    Pending    CLS &
WAKO    ***    ***    ***      

***

   RU    PCT    Pending    CLS &
WAKO    ***    ***    ***      

***

   KR    PCT    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

48

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   JP    PCT    Pending    CLS    ***    ***    ***      

***

   CN    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    DIV    Pending    CLS    ***    ***    ***      

***

   KR    DIV    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Pending    CLS    ***    ***    ***      

***

   KR    EPC    Pending    CLS &
WAKO    ***    ***    ***      

***

   US    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   DE    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    EPC    Granted    CLS    ***    ***    ***    ***    ***

***

   FR    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   GB    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

49

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   JP    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CIP    Granted    CLS    ***    ***    ***    ***    ***

***

   US    CON    Granted    CLS    ***    ***    ***    ***    ***

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

50

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   US    EPP    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   EP    ORD    Pending    CLS    ***    ***    ***      

***

   US    EPP    Pending    CLS    ***    ***    ***      

***

   EP    ORD    Pending    CLS    ***    ***    ***      

***

   US    ORD    Pending    CLS    ***    ***    ***      

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

51

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Pending    CLS    ***    ***    ***      

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   CN    PCT    Pending    CLS    ***    ***    ***      

***

   JP    PCT    Pending    CLS    ***    ***    ***      

***

   EP    PCT    Pending    CLS    ***    ***    ***      

***

   WO    ORD    Pending    CLS    ***    ***    ***      

***

   EP    DIV    Pending    CLS    ***    ***    ***      

***

   US    PCT    Granted    CLS    ***    ***    ***    ***    ***

***

   JP    PCT    Allowed    CLS    ***    ***    ***      

***

   US    ORD    Granted    CLS    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

52

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    DIV    Pending    CLS    ***    ***    ***      

***

   US    PCT    Pending    CLS    ***    ***    ***      

***

   WO    ORD    Pending    CLS    ***    ***    ***      

***

   US    ORD    Pending    CLS    ***    ***    ***      

***

   US    CIP    Pending    CLS    ***    ***    ***      

***

   WO    PCT    Pending    CLS & FWC    ***    ***    ***      

***

   US    PCT    Pending    CLS    ***    ***    ***      

***

   EP    PCT    Pending    CLS    ***    ***    ***      

***

   JP    PCT    Pending    CLS    ***    ***    ***      

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

53

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Pending    CLS    ***    ***    ***      

***

   US    CIP    Pending    CLS    ***    ***    ***      

***

   US    CIP    Pending    CLS    ***    ***    ***      

***

   WO    ORD    Pending    CLS    ***    ***    ***      

***

   WO    CIP    Pending    CLS    ***    ***    ***      

***

   US    ORD    Pending    CLS    ***    ***    ***      

***

   US    ORD    Pending    CLS    ***    ***    ***      

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

54

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   CA    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   JP    ORD    Granted    PENN    ***    ***    ***    ***    ***

***

   US    ORD    Granted    PENN    ***    ***    ***    ***    ***

***

   HK    PIP    Opposed    PENN    ***    ***    ***    ***    ***

***

   US    DIV    Granted    PENN    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

55

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    ORD    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CIP    Granted    PENN    ***    ***    ***    ***    ***

***

   CA    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   HK    EPC    Granted    PENN    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

56

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   IT    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   US    FWC    Granted    PENN    ***    ***    ***    ***    ***

***

   AT    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   CA    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   IT    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    PENN    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

57

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   MX    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   NL    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   SE    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CIP    Granted    PENN    ***    ***    ***    ***    ***

***

   US    DIV    Granted    PENN    ***    ***    ***    ***    ***

***

   JP    DIV    Pending    PENN    ***    ***    ***      

***

   US    RCE    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   CA    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    PENN    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

58

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   JP    PCT    Pending    PENN    ***    ***    ***      

***

   US    FWC    Granted    PENN    ***    ***    ***    ***    ***

***

   CA    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   IT    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    PENN    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

59

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    FWC    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   CA    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   DE    EPP    Granted    PENN    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

60

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    PENN    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    PENN    ***    ***    ***    ***    ***

***

   US    CIP    Granted    PENN    ***    ***    ***    ***    ***

***

   MX    PCT    Pending    PENN    ***    ***    ***      

***

   US    DIV    Granted    PENN    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

61

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    PENN    ***    ***    ***    ***    ***

***

   US    ORD    Granted    ORNL    ***    ***    ***    ***    ***

***

   AT    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   BE    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   CA    PCT    Granted    ORNL    ***    ***    ***    ***    ***

***

   CH    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   CN    PCT    Granted    ORNL    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

62

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   DE    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   DK    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   EP    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   ES    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   FR    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   GB    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   IE    EPP    Granted    ORNL    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

63

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   DE    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   IT    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    ORNL    ***    ***    ***    ***   

***

   KR    PCT    Granted    ORNL    ***    ***    ***    ***    ***

***

   LU    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   MC    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   MX    PCT    Granted    ORNL    ***    ***    ***    ***    ***

***

   NL    EPP    Granted    ORNL    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

64

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   SE    EPP    Granted    ORNL    ***    ***    ***    ***    ***

***

   US    CON    Granted    ORNL    ***    ***    ***    ***    ***

***

   DE    EDV    Granted    ORNL    ***    ***    ***    ***   

***

   EP    EDV    Granted    ORNL    ***    ***    ***    ***   

***

   US    CON    Granted    ORNL    ***    ***    ***    ***    ***

***

   US    CON    Granted    ORNL    ***    ***    ***    ***    ***

***

   EP    EDV    Published    ORNL    ***    ***    ***      

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

65

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    ORNL    ***    ***    ***    ***    ***

***

   US    CON    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    RCE    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    ORD    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    CIP    Granted    LOCK    ***    ***    ***    ***    ***

***

   CA    PCT    Pending    LOCK    ***    ***    ***      

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

66

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   JP    PCT    Pending    LOCK    ***    ***    ***      

***

   EP    EPP    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    ORD    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    DIV    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    ORD    Granted    LOCK    ***    ***    ***    ***    ***

***

   CA    PCT    Granted    LOCK    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

67

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   EP    EPP    Granted    LOCK    ***    ***    ***    ***    ***

***

   JP    PCT    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    CIP    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    ORD    Granted    LOCK    ***    ***    ***    ***    ***

***

   CA    PCT    Pending    LOCK    ***    ***    ***      

***

   EP    EPP    Grantede    LOCK    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

68

--------------------------------------------------------------------------------

Exhibit A: Licensed Patents

Confidential

 

Docket
Number

  

Country

  

Case
Type

  

Status

   App
Owner    App No.    Filing Date   

Application Title

   Patent #    Issue Date

***

   US    CON    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    ORD    Granted    LOCK    ***    ***    ***    ***    ***

***

   US    CON    Granted    LOCK    ***    ***    ***    ***    ***

 

[***] Information has been omitted and filed separately with the Securities and
Exchange Commission. Confidential Treatment has been requested with respect to
the omitted portions.

 

69